Serial dilutions of LILRB1/CD85j/ILT2, His & Avi, Human Antibody were added into Biotinylated Human HLA-G Complex Tetramer, His Tag : Human LILRB1, His Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 27ng/ml.
Immobilized LILRB1/CD85j/ILT2, His & Avi, Human, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB1 Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA.
The purity of LILRB1/CD85j/ILT2, His & Avi, Human is greater than 95% as determined by SEC-HPLC.
LILRB1/CD85j/ILT2, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
LILRB1/CD85j/ILT2, His & Avi, Human
LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.
| Z05593 | |
|
|
|
| ¥46,636.00 | |
|
|
|
|
|
|
| Ask us a question | |
